Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Solid Biosciences (Nasdaq: SLDB) announced that President and CEO Bo Cumbo will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 5:15 p.m. PT (8:15 p.m. ET). A live webcast will be available on the company's Investors Events page, and a replay will be archived for 30 days.
This presentation provides investors and analysts access to management commentary and updates via webcast.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, SLDB gained 3.00%, reflecting a moderate positive market reaction. This price movement added approximately $12M to the company's valuation, bringing the market cap to $428M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus 1 Up
Peers in Biotechnology showed mixed moves, with names like AURA (-2.26%) and ALMS (-6.63%) down, while DMAC gained 6.48%. Momentum scanners only flagged ALMS with a strong upside move, suggesting SLDB’s setup ahead of this conference item appears more stock-specific than part of a broad sector swing.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 16 | Screening panel update | Positive | +1.9% | Duchenne muscular dystrophy added to the U.S. newborn screening panel. |
| Dec 08 | Scientific conference data | Positive | -1.0% | Presentations on AAV-SLB101 and cardiac gene therapy pipeline at CVCT Forum. |
| Dec 01 | Inducement equity grants | Neutral | -2.1% | RSU inducement awards to new hires under the 2024 Inducement Plan. |
| Dec 01 | Regulatory designation | Positive | -4.0% | FDA Rare Pediatric Disease designation for SGT-212 gene therapy in FA. |
| Nov 17 | Licensing agreement | Positive | +2.4% | Non-exclusive license of AAV-SLB101 to Andelyn Biosciences for client use. |
Recent SLDB news, especially clinical and regulatory milestones, has produced mixed price reactions, with some positive updates aligning with gains and others seeing short-term selloffs.
Over the last two months, Solid Biosciences reported several milestones, including FDA Rare Pediatric Disease designation for SGT-212, a licensing deal for AAV-SLB101, and the addition of Duchenne to the U.S. RUSP on Dec. 16, 2025. It also highlighted next-generation capsid data at the CVCT Forum and reported inducement RSU grants. Against this backdrop, today’s J.P. Morgan Healthcare Conference appearance continues a pattern of increasing scientific and corporate visibility.
Market Pulse Summary
This announcement highlights Solid Biosciences’ participation in the 44th J.P. Morgan Healthcare Conference on January 13, 2026, offering a platform to showcase its neuromuscular and cardiac genetic medicine programs. Recent history includes regulatory milestones, licensing activity for AAV-SLB101, and progress across SGT-003 and SGT-212. Investors may watch for any new clinical details, strategic updates, or partnering commentary shared during the presentation and archived 30-day webcast.
AI-generated analysis. Not financial advice.
CHARLESTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 5:15 p.m. PT (8:15 p.m. ET).
A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
When will Solid Biosciences (SLDB) present at the 44th Annual J.P. Morgan Healthcare Conference?
Who from Solid Biosciences will present at the JP Morgan conference for SLDB?
How can investors watch the SLDB presentation at the J.P. Morgan conference?
Will Solid Biosciences (SLDB) provide a replay of the J.P. Morgan presentation?
What time is the Solid Biosciences (SLDB) webcast in Eastern Time?
